Tove Tuntland
Publications by Year
Research Areas
Neuroblastoma Research and Treatments, Cancer therapeutics and mechanisms, HIV/AIDS drug development and treatment, Cancer Treatment and Pharmacology, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors(2010)596 cited
- → Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness(2016)408 cited
- → Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials(2013)408 cited
- → Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery(2011)347 cited
- → Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist(2010)325 cited
- → Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research(2014)224 cited
- → Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility(2008)221 cited
- → Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2(2006)197 cited
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as l-Glutamine Replacements(1999)189 cited
- → Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator(2013)165 cited